Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421618 | 1.00 | PDPK1 (0.44) | PDPK1GDADCPSRENDHFR | |
| SCHEMBL4106056 | 0.79 | DYRK1A (0.50) | DYRK1A | |
| SCHEMBL4872319 | 0.79 | DYRK1A (0.33) | PDPK1DCPSRENDHFRDYRK1A | |
| SCHEMBL23889230 | 0.79 | DYRK1A (0.33) | DCPSRENDHFRDYRK1A | |
| SCHEMBL4838531 | 0.79 | DYRK1A (0.41) | DYRK1A | |
| SCHEMBL24175031 | 0.79 | NPY5R (0.46) | RENDYRK1A | |
| SCHEMBL20274839 | 0.79 | REN (0.41) | PDPK1GDADCPSRENDHFR | |
| SCHEMBL21727172 | 0.75 | DYRK1A (0.31) | RENDYRK1A | |
| SCHEMBL31745118 | 0.75 | PIK3CA (0.31) | DYRK1A | |
| SCHEMBL18194317 | 0.75 | CHUK (0.40) | RENDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290420-B1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | UNIV XIAMEN (CN) | 2020-12-09 | — | — | EP | claimed |
| CN-106459058-B | Compound and composition as 7 agonist of TOLL- sample receptor | 诺华股份有限公司 | 2019-07-05 | — | — | CN | claimed |
| CN-106232603-B | Compound and composition as 7 agonist of TOLL- sample receptor | 诺华股份有限公司 | 2019-07-05 | — | — | CN | claimed |
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2018-11-01 | — | — | US | claimed |
| EP-3290420-A1 | PYRIMIDINE PYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | Xiamen University (CN) | 2018-03-07 | — | — | EP | claimed |
| WO-2017205762-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | claimed |
| WO-2024118785-A2 | TLR7 AGONISTS AND ANTIBODY-DRUG-CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114269749-A | 5H-pyrrolo [3,2-d ] pyrimidine-2, 4-diamino compounds and antibody conjugates thereof | 苏特罗生物制药公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269749-A | 5H-pyrrolo [3,2-d ] pyrimidine-2, 4-diamino compounds and antibody conjugates thereof | 苏特罗生物制药公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114269749-A | 5H-pyrrolo [3,2-d ] pyrimidine-2, 4-diamino compounds and antibody conjugates thereof | 苏特罗生物制药公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2020252043-A1 | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| CN-106459058-B | Compound and composition as 7 agonist of TOLL- sample receptor | 诺华股份有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-106232603-B | Compound and composition as 7 agonist of TOLL- sample receptor | 诺华股份有限公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-106220608-B | Diphenylamino pyrimidine and triaizine compounds, its Pharmaceutical composition and purposes | 安润医药科技（苏州）有限公司 | 2018-11-27 | — | — | CN | disclosed |
| CN-108430515-A | Include the antibody conjugates of TOLL- sample receptor stimulating agents | 诺华股份有限公司 | 2018-08-21 | — | — | CN | disclosed |
| WO-2017205762-A1 | INHIBITORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE | PHARMACYCLICS LLC (US) | 2017-11-30 | — | — | WO | disclosed |
| EP-3137468-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | Novartis AG (CH) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015168279-A1 | COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS | NOVARTIS AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312508-A1 | PYRIMIDOPYRROLE COMPOUNDS, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | TPMT, DHPS, TYMP | PDPK1 975/4885GDA 1170/4885DCPS 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.